Latest Content

The FDA has granted traditional approval to brexucabtagene autoleucel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.

Use of ruxolitinib before, during, and after allogeneic stem cell transplant was associated with low rates of GVHD in myelofibrosis.

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Shubham Pant, MD, MBBS, discusses recent treatment advancements across gastrointestinal malignancies.

Read a refresh of the top FDA news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval.

A study identified genetic mutations tied to earlier diagnosis and faster progression of myelodysplastic syndromes.

Cogent Biosciences has submitted an NDA for bezuclastinib for patients with GIST who received prior imatinib.

The FDA has extended the PDUFA date for the Orca-T BLA to July 6, 2026.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

Read our recap of top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

Neoadjuvant anbenitamab plus albumin-bound docetaxel yielded a significant tpCR benefit vs standard therapy in HER2-positive early breast cancer.

A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy.

Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.